Quanterix is on a mission to change the way healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease. To make this vision reality, the company brought together the most experienced management team, renowned scientists, industry-leading investors and expert advisors to form a collaborative ecosystem, united through the common goal of advancing the science of precision health. Its digital health solution, Simoa, gives researchers an ultrasensitive look into critical biomarkers in numerous therapeutic areas – oncology, neurology, cardiology, inflammation and infectious disease – with the power to transform medicine, allowing for prevention, early diagnosis, and next generation treatments. Quanterix’s technology has been cited in nearly 300 peer-reviewed publications. Despite warnings of a tough IPO environment, Quanterix held an extremely successful IPO in 2017 and is continuing to beat analyst expectations.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):